December 3, 2010

Effect of metformin on cardiovascular events and mortality: a meta‐analysis of randomized clinical trials

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Available evidence seems to exclude any overall harmful effect of metformin on cardiovascular risk, suggesting a possible benefit versus placebo/no treatment. The observed detrimental effect of the combination with sulphonylureas deserves further investigation.

Me gusta

Guardar

Cite This Study

Lamanna et al. (Fri,) studied this question.

synapsesocial.com/papers/69d7392af07a12db70b8a63a https://doi.org/https://doi.org/10.1111/j.1463-1326.2010.01349.x

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1International Diabetes Federation 20172018 · 13,553 citations
2Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.1998 · 4,300 citations
3Glycemic Control With Diet, Sulfonylurea, Metformin, or Insulin in Patients With Type 2 Diabetes Mellitus<SUBTITLE>Progressive Requirement for Multiple Therapies (UKPDS 49)</SUBTITLE>1999 · 2,383 citations
4Metabolic and Hemodynamic Effects of Metformin and Glibenclamide in Normotensive NIDDM Patients1993 · 81 citations
5Mortality Trends in Subjects With and Without Diabetes During 33 Years of Follow-up2009 · 87 citations

Me gusta

Guardar